AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca’s recent clinical study, officially titled ‘A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID),’ aimed to assess the efficacy and safety of benralizumab in treating patients with severe nasal polyposis. This study was significant as it sought to provide a new treatment option for individuals suffering from this chronic condition.
Intervention/Treatment: The study tested benralizumab, a biological treatment administered subcutaneously. Benralizumab was intended to reduce nasal polyps and improve symptoms in patients with eosinophilic chronic rhinosinusitis.
Study Design: This was an interventional, randomized, double-blind, placebo-controlled study with a parallel design. It involved triple masking, meaning that participants, care providers, and investigators were unaware of the treatment allocations. The primary purpose was treatment-focused.
Study Timeline: The study began on October 23, 2019, but was terminated before completion. The last update was submitted on September 5, 2025. These dates are crucial for understanding the study’s progress and its premature termination.
Market Implications: The termination of this study could impact AstraZeneca’s stock performance and investor sentiment, as it may delay the introduction of a potentially lucrative treatment. Competitors in the pharmaceutical industry may see this as an opportunity to advance their own treatments for similar conditions.
The study has been terminated, and further details are available on the ClinicalTrials portal.